Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease

This study has been completed.
Sponsor:
Collaborator:
Ohio State University
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00004771
First received: February 24, 2000
Last updated: June 23, 2005
Last verified: December 2001

February 24, 2000
June 23, 2005
October 1992
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00004771 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Not Provided

OBJECTIVES:

I. Evaluate the effects of androgen suppression with leuprolide and androgen replacement with testosterone enanthate on muscle strength in men with Kennedy's disease or other motor neuron disease.

PROTOCOL OUTLINE:

All patients receive androgen suppression with leuprolide acetate injections every 4 weeks for 6 months, plus hormone replacement therapy with testosterone enanthate injections every week for 24 weeks.

Interventional
Phase 2
Primary Purpose: Treatment
  • Spinal Muscular Atrophy
  • Amyotrophic Lateral Sclerosis
  • Spinobulbar Muscular Atrophy
  • Drug: leuprolide
  • Drug: testosterone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
Not Provided
Not Provided

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Men aged 18 and over with motor neuron disease, i.e.:

  • X-linked spinal and bulbar muscular atrophy (Kennedy's disease)
  • Confirmed by androgen receptor, exon-1 mutation genotype
  • Amyotrophic lateral sclerosis
  • Spinal muscular atrophy

Significant muscle weakness on manual muscle testing

No prisoners

No mental disability

Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00004771
199/11792, OSU-92H0325
Not Provided
Not Provided
National Center for Research Resources (NCRR)
Ohio State University
Study Chair: Jerry R. Mendell Ohio State University
Office of Rare Diseases (ORD)
December 2001

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP